A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

PURPOSE: Cediranib is a multi-tyrosine kinase inhibitor targeting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This phase II study was conducted to assess activity and tolerability of single-agent cediranib in recurre...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Gynecol Oncol
मुख्य लेखकों: Bender, David, Sill, Michael W., Lankes, Heather A., Reyes, Henry D., Darus, Christopher J., Delmore, James E., Rotmensch, Jacob, Gray, Heidi J., Mannel, Robert S., Schilder, Jeanne M., Hunter, Mark I., McCourt, Carolyn K., Samuelson, Megan I., Leslie, Kimberly K.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2015
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4642817/
https://ncbi.nlm.nih.gov/pubmed/26186911
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2015.07.018
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन